<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04669132</url>
  </required_header>
  <id_info>
    <org_study_id>38285020.8.0000.0072</org_study_id>
    <nct_id>NCT04669132</nct_id>
  </id_info>
  <brief_title>Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer</brief_title>
  <acronym>OLNEPA</acronym>
  <official_title>Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Brasileiro de Controle do Cancer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Brasileiro de Controle do Cancer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a longitudinal, one arm, prospective phase II study, designed to evaluate the&#xD;
      efficacy of Olanzapine Netupitant and Palonosetron in the controll of nausea and vomiting&#xD;
      induced by highly emetogenic chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The population of the study is women diagnosed with breast cancer, who will start&#xD;
      chemotherapy (Doxorubicine and Cyclophosfamide). We will evaluate the control of nausea and&#xD;
      vomiting in the first cycle of chemotherapy, utilizing Netupitant (300mg) + palonosetron&#xD;
      (0,56mg) in day 1 and Olanzapine 5mg starting on Day 0, given once a day for five days. The&#xD;
      primary endpoint of this study is complete response rate (no nausea, no emesis no use of&#xD;
      rescue medication).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2020</start_date>
  <completion_date type="Anticipated">January 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 17, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>6 days after chemotherapeutic administration</time_frame>
    <description>Defined as no vomiting episodes and no rescue medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients no Vomiting</measure>
    <time_frame>For the following time periods: 0-24 hours (acute), 24+ to 120 hours (delayed), and 0-120 hours (overall)</time_frame>
    <description>Defined as no nausea, no emetic episodes, included patients that use of rescue medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with presence of nausea</measure>
    <time_frame>For the following time periods: 0-24 hours (acute), 24+ to 120 hours (delayed), and 0-120 hours (overall)</time_frame>
    <description>Patients with presence of nausea graded &lt;25mm according to Visual Analogue Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with no nausea</measure>
    <time_frame>For the following time periods: 0-24 hours (acute), 24+ to 120 hours (delayed), and 0-120 hours (overall)</time_frame>
    <description>Patients with no nausea graded &lt; 5mm according to Visual Analogue Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients no use of rescue medications</measure>
    <time_frame>For the following time periods: 0-24 hours (acute), 24+ to 120 hours (delayed), and 0-120 hours (overall)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Nausea Post Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Olanzapine + Netupitanto + Palonosetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine 5 mg/day d 0-4 + Netupitanto 300 mg/day d 1 + Palonosetron 0.56 mg/day d 1;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>- Olanzapine 5mg, administered once daily, during 5 days (day before chemotherapy, the D day of the chemotherapy and 3 day after chemotherapy)</description>
    <arm_group_label>Olanzapine + Netupitanto + Palonosetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netupitant</intervention_name>
    <description>- Netupitanto 300 mg, once daily, on chemotherapy day;</description>
    <arm_group_label>Olanzapine + Netupitanto + Palonosetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonesetron</intervention_name>
    <description>- Palonosetron 0.56 mg, once daily, on chemotherapy day;</description>
    <arm_group_label>Olanzapine + Netupitanto + Palonosetron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Breast cancer hitologically confirmed&#xD;
&#xD;
          -  18 Years and older (Adult, Older Adult)&#xD;
&#xD;
          -  Patients about to start use of Doxorubicine 60mg/m2 + Cyclophosfamide 600mg/m2&#xD;
&#xD;
          -  No previous chemotherapy for breast cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients not capable of completing the questionnaire&#xD;
&#xD;
          -  Patients with other condition that could cause nausea and emesis&#xD;
&#xD;
          -  Use of opioids&#xD;
&#xD;
          -  Use of antipsychotic medications&#xD;
&#xD;
          -  Patients not capable of taking medications orally&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Camilla Rebouças, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Brasileiro de Controle do Cancer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Camilla Rebouças, MD</last_name>
    <phone>+5571982998870</phone>
    <email>cdereboucas@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Felipe Cruz, MD</last_name>
    <phone>+5511994466537</phone>
    <email>felipemcruz@yahoo.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IBCC Oncologia</name>
      <address>
        <city>São Paulo</city>
        <zip>03102002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camilla Rebouças</last_name>
      <phone>+5571982998870</phone>
      <email>cdereboucas@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Felipe Cruz</last_name>
      <phone>+5511994466537</phone>
      <email>felipemcruz@yahoo.com.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Razvi Y, Chan S, McFarlane T, McKenzie E, Zaki P, DeAngelis C, Pidduck W, Bushehri A, Chow E, Jerzak KJ. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer. 2019 Jan;27(1):87-95. doi: 10.1007/s00520-018-4464-y. Epub 2018 Oct 3. Review.</citation>
    <PMID>30284039</PMID>
  </reference>
  <reference>
    <citation>Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016 Sep;27(suppl 5):v119-v133.</citation>
    <PMID>27664248</PMID>
  </reference>
  <reference>
    <citation>Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003 Oct;14(10):1570-7.</citation>
    <PMID>14504060</PMID>
  </reference>
  <reference>
    <citation>Wang H, Wang Y, Rayburn ER, Hill DL, Rinehart JJ, Zhang R. Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Int J Oncol. 2007 Apr;30(4):947-53.</citation>
    <PMID>17332934</PMID>
  </reference>
  <reference>
    <citation>Kim MH, Kim DW, Park S, Kim JH, Lee KY, Hwang J, Yoo YC. Single dose of dexamethasone is not associated with postoperative recurrence and mortality in breast cancer patients: a propensity-matched cohort study. BMC Cancer. 2019 Mar 20;19(1):251. doi: 10.1186/s12885-019-5451-5.</citation>
    <PMID>30894164</PMID>
  </reference>
  <reference>
    <citation>Chen YX, Wang Y, Fu CC, Diao F, Song LN, Li ZB, Yang R, Lu J. Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells. Endocr Relat Cancer. 2010 Jan 29;17(1):39-50. doi: 10.1677/ERC-08-0296. Print 2010 Mar.</citation>
    <PMID>19776289</PMID>
  </reference>
  <reference>
    <citation>Obradović MMS, Hamelin B, Manevski N, Couto JP, Sethi A, Coissieux MM, Münst S, Okamoto R, Kohler H, Schmidt A, Bentires-Alj M. Glucocorticoids promote breast cancer metastasis. Nature. 2019 Mar;567(7749):540-544. doi: 10.1038/s41586-019-1019-4. Epub 2019 Mar 13.</citation>
    <PMID>30867597</PMID>
  </reference>
  <reference>
    <citation>de Castro Baccarin AL, Irene MN, de Iracema Gomes Cubero D, Luz AS, Castro SN, Sordi R, Móz LES, Del Giglio A. The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients. Support Care Cancer. 2019 Mar;27(3):927-931. doi: 10.1007/s00520-018-4381-0. Epub 2018 Aug 1.</citation>
    <PMID>30069696</PMID>
  </reference>
  <reference>
    <citation>Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013 Jun;21(6):1655-63. doi: 10.1007/s00520-012-1710-6. Epub 2013 Jan 12.</citation>
    <PMID>23314603</PMID>
  </reference>
  <reference>
    <citation>Cruz FM, de Iracema Gomes Cubero D, Taranto P, Lerner T, Lera AT, da Costa Miranda M, da Cunha Vieira M, de Souza Fêde AB, Schindler F, Carrasco MM, de Afonseca SO, Pinczowski H, del Giglio A. Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study. Support Care Cancer. 2012 Mar;20(3):601-6. doi: 10.1007/s00520-011-1138-4. Epub 2011 Apr 5.</citation>
    <PMID>21465325</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Brasileiro de Controle do Cancer</investigator_affiliation>
    <investigator_full_name>Camilla Vieira de Rebouças</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>olanzapine</keyword>
  <keyword>emetogenic</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>breast cancer</keyword>
  <keyword>nausea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

